Abstract
Background: Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology.
Method: We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria. Technical reports on tofacitinib from U.S. Food and Drug Administration and European Medical Agency were also included. Results: Forty-three papers were included in this review. We report current data on tofacitinib chemical properties, pharmacology, non-clinical toxicity, as well as efficacy and safety in potential new indications in dermatology: psoriasis, alopecia areata, vitiligo, atopic dermatitis and nail dystrophy associated with alopecia areata. Conclusion: JAK/STAT pathway has an important role in the pathogenesis of psoriasis, alopecia areata, atopic dermatitis, and vitiligo. Despite encouraging efficacy, due to concerns about the overall safety profile of tofacitinib, additional studies will have to determine the adequate risk-to-benefit ratio.Keywords: Tofacitinib, CP690550, protein kinase inhibitor, JAK/STAT pathway, small molecule, psoriasis, alopecia areata, vitiligo.
Current Medicinal Chemistry
Title:Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Volume: 24 Issue: 11
Author(s): Kresimir Kostovic*, Sandra J. Gulin, Zrinka B. Mokos and Romana Ceovic
Affiliation:
- Department of Dermatovenereology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Salata 4, 10000 Zagreb,Croatia
Keywords: Tofacitinib, CP690550, protein kinase inhibitor, JAK/STAT pathway, small molecule, psoriasis, alopecia areata, vitiligo.
Abstract: Background: Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology.
Method: We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria. Technical reports on tofacitinib from U.S. Food and Drug Administration and European Medical Agency were also included. Results: Forty-three papers were included in this review. We report current data on tofacitinib chemical properties, pharmacology, non-clinical toxicity, as well as efficacy and safety in potential new indications in dermatology: psoriasis, alopecia areata, vitiligo, atopic dermatitis and nail dystrophy associated with alopecia areata. Conclusion: JAK/STAT pathway has an important role in the pathogenesis of psoriasis, alopecia areata, atopic dermatitis, and vitiligo. Despite encouraging efficacy, due to concerns about the overall safety profile of tofacitinib, additional studies will have to determine the adequate risk-to-benefit ratio.Export Options
About this article
Cite this article as:
Kostovic Kresimir*, Gulin J. Sandra, Mokos B. Zrinka and Ceovic Romana, Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology, Current Medicinal Chemistry 2017; 24 (11) . https://dx.doi.org/10.2174/1874467210666170113104503
DOI https://dx.doi.org/10.2174/1874467210666170113104503 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CCR2 Antagonists
Current Topics in Medicinal Chemistry Leptin and Inflammation
Current Immunology Reviews (Discontinued) Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry Applying Knowledge of Enzyme Biochemistry to the Prediction of Functional Sites for Aiding Drug Discovery
Current Topics in Medicinal Chemistry <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy The Coronin Family and Human Disease
Current Protein & Peptide Science Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Transmucosal Delivery of Linagliptin for the Treatment of Type- 2 Diabetes Mellitus by Ultra-Thin Nanofibers
Current Drug Delivery Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science